Literature DB >> 3485112

Potentiation of human immunoglobulin E synthesis by plasma immunoglobulin E binding factors from patients with the hyperimmunoglobulin E syndrome.

D Y Leung, R Frankel, N Wood, R S Geha.   

Abstract

Affinity-purified IgE-binding factors from the plasma of patients with the hyper IgE syndrome (HIE) were assessed for their capacity to enhance IgE synthesis by B cells derived from patients with allergic rhinitis or normal nonatopic donors. IgE-binding factors from three of four HIE patients enhanced IgE synthesis by B cells from patients with perennial allergic rhinitis, or with seasonal allergic rhinitis (SAR) and recent pollen exposure, but did not enhance IgE synthesis by B cells from nonatopic donors or from SAR patients with no recent pollen exposure. IgG synthesis was not affected by HIE IgE binding factors. In contrast, IgE binding factors from three of three nonatopic donors failed to enhance IgE or IgG synthesis. Plasma IgE-binding factors from the fourth patient with HIE contained a mixture of IgE-potentiating activity and IgE-suppressive activity. These two activities could be separated on concanavalin A Sepharose or peanut agglutinin agarose columns. Human IgE potentiating factor, but not IgE suppressive factor, had affinity for concanavalin A but not peanut agglutinin and fractionated into two peaks on gel filtration over Sephadex G-75: one peak with a molecular size of approximately 15,000 D and the other with a molecular size of approximately 60,000 D. The isolation of functional IgE binding factors which potentiate IgE synthesis from the plasma of patients with HIE suggests that IgE-binding factors play an important role in the in vivo regulation of IgE synthesis in man.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485112      PMCID: PMC423491          DOI: 10.1172/JCI112395

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Extreme hyperimmunoglobulinemia E and undue susceptibility to infection.

Authors:  R H Buckley; B B Wray; E Z Belmaker
Journal:  Pediatrics       Date:  1972-01       Impact factor: 7.124

2.  cDNA clones encoding IgE-binding factors from a rat-mouse T-cell hybridoma.

Authors:  C L Martens; T F Huff; P Jardieu; M L Trounstine; R L Coffman; K Ishizaka; K W Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

3.  Regulatory role of IgE-binding factors from rat T lymphocytes. V. The carbohydrate moieties in IgE-potentiating factors and IgE-suppressive factors.

Authors:  J Yodoi; M Hirashima; K Ishizaka
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

4.  Immunoglobulin E (IgE) and IgE-containing cells in human gastrointestinal fluids and tissues.

Authors:  W R Brown; B K Borthistle; S T Chen
Journal:  Clin Exp Immunol       Date:  1975-05       Impact factor: 4.330

5.  Formation of IgE binding factors by human T lymphocytes.

Authors:  K Ishizaka; K Sandberg
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

6.  Induction of human IgE synthesis by a factor derived from T cells of patients with hyper-IgE states.

Authors:  J A Saryan; D Y Leung; R S Geha
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

7.  Regulatory role of IgE-binding factors from rat T lymphocytes. IV. Formation of IgE-binding factors in rats treated with complete Freund's adjuvant.

Authors:  M Hirashima; J Yodoi; K Ishizaka
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

8.  Regulatory role of IgE-binding factors from rat T lymphocytes. I. Mechanism of enhancement of IgE response by IgE-potentiating factor.

Authors:  M Suemura; J Yodoi; M Hirashima; K Ishizaka
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

9.  Regulatory role of IgE-binding factors from rat T lymphocytes. III. IgE-specific suppressive factor with IgE-binding activity.

Authors:  M Hirashima; J Yodoi; K Ishizaka
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

10.  Deficiency of suppressor T cells in the hyperimmunoglobulin E syndrome.

Authors:  R S Geha; E Reinherz; D Leung; K T McKee; S Schlossman; F S Rosen
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

View more
  7 in total

1.  Effect of cytokines on spontaneous and allergen-induced CD23 expression, sCD23 release and Ig(E,G) synthesis from peripheral blood lymphocytes.

Authors:  T Pfeil; A Fischer; J Bujanowski-Weber; H Luther; P Altmeyer; W König
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

Review 2.  Control of IgE synthesis in man.

Authors:  D Y Leung; R S Geha
Journal:  J Clin Immunol       Date:  1986-07       Impact factor: 8.317

3.  Cell-cell interactions for CD23 expression and soluble CD23 release from peripheral lymphocytes of atopic donors.

Authors:  K Kicza; A Fischer; T Pfeil; J Bujanowski-Weber; W König
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

4.  Regulation of CD23 expression, soluble CD23 release and immunoglobulin synthesis of peripheral blood lymphocytes by glucocorticoids.

Authors:  A Fischer; W König
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

5.  Detection and characterization of IgE-binding factors (IgE-BF) within supernatants of the cell line RPMI-8866, normal human sera and sera from atopic patients.

Authors:  J Bujanowski-Weber; I Knöller; B Brings; T Pfeil; W König
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

6.  Selective deficiency of interferon-gamma production in the hyper-IgE syndrome. Relationship to in vitro IgE synthesis.

Authors:  R Paganelli; E Scala; M R Capobianchi; E Fanales-Belasio; G D'Offizi; M Fiorilli; F Aiuti
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

7.  Expression of low-affinity receptor for IgE (Fc epsilon RII, CD23) and IgE-BF (soluble CD23) release by lymphoblastoid B-cell line RPMI-8866 and human peripheral lymphocytes of normal and atopic donors.

Authors:  J Bujanowski-Weber; B Brings; I Knöller; T Pfeil; W König
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.